Bristol-Myers, Pfizer Report Stroke, Systemic Embolism, Major Bleeding Uncommon in Eliquis Phase 3 ARISTOTLE Trial

Bristol-Myers Squibb Company
BMY
and Pfizer Inc.
PFE
today announced results of a post-hoc subanalysis from the Phase III ARISTOTLE trial. Patients with nonvalvular atrial fibrillation (NVAF) who are anticoagulated to reduce the risk of stroke often undergo procedures for which temporary discontinuation of the anticoagulant prior to and following the procedure is sometimes warranted. This subanalysis describes the overall rates of key post-procedural outcomes, such as stroke or systemic embolism and major bleeding, among Eliquis and warfarin patients who underwent a procedure during the ARISTOTLE trial, and examined any differences in post-procedural events according to whether or not study drug was interrupted. This subanalysis was presented today at the ESC
See full press release

Posted In: NewsGuidanceContractsManagementM&AGlobal